KIN-2787 for advanced solid tumors with BRAF or NRAS mutations
Part of Cancer, Hormones & metabolism, Lungs & breathing, Skin clinical trials.
This trial tests a new drug, KIN-2787, for people with advanced solid tumors that have specific changes (mutations) in the BRAF or NRAS genes. The drug is designed to target these changes and may help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced or metastatic solid tumor that has not responded to standard treatment.
- Your tumor must have a BRAF or NRAS mutation, as confirmed by a prior genetic test.
- You need to be able to take oral medications by mouth.
- You must be in generally good health (able to perform daily activities).
- You cannot have had certain prior treatments or have certain other medical conditions, as detailed in the full criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BI 3810944 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
This Phase 2 trial tests binimetinib plus imatinib in people with advanced melanoma that cannot be removed with surgery and that has a KIT mutation. It’s for melanoma that has gotten worse after standard treatment (or where standard treatment isn’t possible or tolerated).
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.